KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Accumulated Expenses (2017 - 2025)

Teva Pharmaceutical Industries' Accumulated Expenses history spans 9 years, with the latest figure at $739.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 18.43% year-over-year to $739.0 million, compared with a TTM value of $739.0 million through Dec 2025, up 18.43%, and an annual FY2025 reading of $739.0 million, up 18.43% over the prior year.
  • Accumulated Expenses for Q4 2025 was $739.0 million at Teva Pharmaceutical Industries, up from $561.0 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $739.0 million in Q4 2025, with the low at $432.0 million in Q1 2023.
  • Average Accumulated Expenses over 5 years is $533.6 million, with a median of $518.5 million recorded in 2021.
  • Year-over-year, Accumulated Expenses decreased 17.81% in 2021 and then grew 18.43% in 2025.
  • Tracing TEVA's Accumulated Expenses over 5 years: stood at $563.0 million in 2021, then grew by 0.53% to $566.0 million in 2022, then rose by 7.95% to $611.0 million in 2023, then increased by 2.13% to $624.0 million in 2024, then grew by 18.43% to $739.0 million in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Accumulated Expenses are $739.0 million (Q4 2025), $561.0 million (Q3 2025), and $481.0 million (Q2 2025).